Jorge Plutzky Selected Research

Thiazolidinediones

9/2008	The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.
1/2007	Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.
1/2005	Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome.
12/2003	The vascular biology of atherosclerosis.
11/2003	Peroxisome proliferator activated receptor gamma and its activation in the treatment of insulin resistance and atherosclerosis: issues and opportunities.
8/2003	The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis.
11/2002	Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions.
11/2002	Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets.
1/2002	Peroxisome proliferator-activated receptors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jorge Plutzky Research Topics

Disease

23	Inflammation (Inflammations) 01/2021 - 11/2002
22	Atherosclerosis 01/2020 - 01/2002
20	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 01/2002
18	Type 2 Diabetes Mellitus (MODY) 01/2022 - 05/2003
14	Insulin Resistance 01/2018 - 11/2002
8	Dyslipidemias (Dyslipidemia) 01/2019 - 01/2002
7	Obesity 11/2020 - 06/2007
6	Hypertension (High Blood Pressure) 07/2022 - 01/2005
5	Diabetes Mellitus 01/2022 - 02/2007
5	Myocardial Infarction 01/2021 - 05/2003
5	Weight Loss (Weight Reduction) 10/2020 - 07/2010
5	Metabolic Syndrome (Dysmetabolic Syndrome X) 11/2008 - 01/2005
4	Hypercholesterolemia 01/2022 - 10/2010
4	Stroke (Strokes) 01/2021 - 08/2011
4	Coronary Artery Disease (Coronary Atherosclerosis) 05/2018 - 02/2015
3	Heart Failure 12/2020 - 08/2013
3	Thrombosis (Thrombus) 11/2020 - 05/2003
3	Hyperglycemia 11/2020 - 02/2009
3	Carotid Artery Diseases 06/2020 - 10/2010
3	Hypertriglyceridemia 04/2012 - 06/2011
2	Vascular Diseases (Vascular Disease) 05/2022 - 01/2012
2	Hypoglycemia (Reactive Hypoglycemia) 01/2022 - 10/2020
2	Prediabetic State (Prediabetes) 01/2022 - 08/2011
2	Rheumatoid Arthritis 01/2021 - 01/2018
2	Neoplasms (Cancer) 01/2021 - 06/2012
2	Overweight 11/2020 - 01/2018
2	Chronic Renal Insufficiency 10/2020 - 01/2018
2	Peripheral Arterial Disease 01/2015 - 08/2011
1	Fibrosis (Cirrhosis) 05/2022
1	Cognitive Dysfunction 01/2022
1	Non-alcoholic Fatty Liver Disease 01/2022
1	Heart Diseases (Heart Disease) 11/2020
1	Injection Site Reaction 10/2018
1	Myalgia 05/2018
1	Muscular Diseases (Myopathy) 05/2018

Drug/Important Bio-Agent (IBA)

16	LipidsIBA 01/2022 - 03/2003
15	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 11/2012 - 01/2002
14	Glucose (Dextrose)FDA LinkGeneric 10/2020 - 11/2002
11	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022 - 02/2007
10	Triglycerides (Triacylglycerol)IBA 01/2019 - 01/2002
9	PPAR alphaIBA 01/2019 - 04/2002
9	ThiazolidinedionesIBA 09/2008 - 01/2002
8	LDL CholesterolIBA 07/2022 - 05/2008
8	Insulin (Novolin)FDA Link 10/2020 - 01/2002
8	PPAR gammaIBA 06/2010 - 04/2002
6	oxidized low density lipoproteinIBA 01/2022 - 10/2003
6	CholesterolIBA 01/2018 - 08/2007
5	HDL CholesterolIBA 07/2022 - 01/2002
5	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2007
5	Proteins (Proteins, Gene)FDA Link 01/2017 - 08/2007
5	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 08/2007 - 01/2002
5	LigandsIBA 08/2007 - 01/2002
4	RetinoidsIBA 01/2020 - 01/2012
4	ApolipoproteinsIBA 06/2011 - 11/2008
4	Pioglitazone (Actos)FDA Link 10/2010 - 05/2005
3	CalciumIBA 05/2022 - 06/2008
3	LDL Lipoproteins (beta Lipoproteins)IBA 01/2021 - 04/2003
3	Transcription Factors (Transcription Factor)IBA 08/2013 - 01/2002
3	Fibric Acids (Fibrates)IBA 08/2007 - 01/2002
3	Lipoproteins (Lipoprotein)IBA 08/2007 - 03/2003
2	Angiotensin IIIBA 05/2022 - 11/2016
2	Hypoglycemic Agents (Hypoglycemics)IBA 01/2022 - 10/2020
2	Interleukin-6 (Interleukin 6)IBA 01/2021 - 01/2015
2	C-Reactive ProteinIBA 01/2021 - 01/2015
2	Glucagon-Like Peptide 1 (GLP 1)IBA 11/2020 - 07/2010
2	Glucagon-Like Peptide-1 Receptor AgonistsIBA 10/2020 - 07/2010
2	AdiponectinIBA 01/2018 - 01/2012
2	ArrestinIBA 01/2017 - 06/2010
2	Matrix Metalloproteinases (MMPs)IBA 11/2016 - 10/2010
2	ChromatinIBA 05/2016 - 08/2013
2	Blood Glucose (Blood Sugar)IBA 02/2016 - 02/2009
2	Vitamin A (Retinol)FDA LinkGeneric 07/2012 - 01/2012
2	IncretinsIBA 11/2011 - 07/2010
2	Fatty Acids (Saturated Fatty Acids)IBA 04/2011 - 08/2007
2	EnzymesIBA 07/2010 - 06/2007
2	Rosiglitazone (Avandia)FDA Link 01/2009 - 09/2008
2	HDL LipoproteinsIBA 11/2008 - 11/2008
2	PPAR-gamma AgonistsIBA 09/2008 - 05/2005
2	Fenofibrate (CiL)FDA LinkGeneric 09/2007 - 02/2007
1	Interleukin-9 (Interleukin 9)IBA 05/2022
1	RNA (Ribonucleic Acid)IBA 05/2022
1	AntibodiesIBA 05/2022
1	CollagenIBA 05/2022
1	Ezetimibe (Zetia)FDA Link 12/2021
1	8- hydroxy- 2,2,14,14- tetramethylpentadecanedioic acidIBA 12/2021
1	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2021
1	Antipsychotic Agents (Antipsychotics)IBA 01/2021
1	Troponin T (Troponin T1)IBA 01/2021
1	sigma-2 receptorIBA 01/2021
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2021
1	Lipoprotein(a)IBA 01/2021
1	semaglutideIBA 11/2020
1	Cytochrome P450 Family 7IBA 01/2020
1	Apolipoprotein C-IIIIBA 01/2020
1	(2E,4E,6E,10E)- 3,7,11,15- tetramethyl- 2,4,6,10,14- hexadecapentaenoic acidIBA 01/2020
1	alirocumabIBA 10/2018

Therapy/Procedure

19	Therapeutics 01/2022 - 11/2002
3	Glycemic Control 10/2020 - 01/2005
2	Transplantation 04/2012 - 04/2002
1	Duration of Therapy 01/2021